經(jīng)銷協(xié)議以下簡(jiǎn)稱本由雙方于年月日在簽署生效

經(jīng)銷協(xié)Distribution ]日在簽署生效：ThisDistributionAgreement(hereinafterreferredtoasthis“Agreement”)ismadeandenteredintobyandbetweenthefollowingpartieson[ ],inShanghai:愛(ài)的發(fā)制藥，一家根據(jù) （以下簡(jiǎn)稱“中國(guó)”）法律成并存續(xù)的公司，地址位于 市青浦區(qū)318國(guó)道16號(hào)橋南首前云路278號(hào)（以下簡(jiǎn)稱“甲方”）；ShanghaiEthypharmCo.,.,alimitedliabilitycompanyestablishedandexistingunderthelawsofPeople’sRepublicofChina(hereinafterreferredtoas“China”,“Chinese”or“PRC”),witharegisteredaddressat278QianYunRoad,SouthofBridge16,NationalHighway318,XuJing,QingpuDistrict,Shanghai(hereinafterreferredtoas“PartyA”). ]，一家根據(jù)中國(guó)法律成立并存續(xù)的公司，地址位于 （以下簡(jiǎn)稱“乙方”） ],alimitedliabilityestablishedandexistingunderthelawsofPRC,witharegisteredaddressat (hereinafterreferredtoasthe“Party本協(xié)議中，甲方和乙方單稱為“一方”，合稱為InthisAgreement,PartyAandPartyBarereferredtoindividuallyasa“Party”andtogetherasthe“Parties”.鑒于PartyAisapharmaceuticalmanufacturingcompanywithlegalqualificationsandagoodreputationandPartyBisapharmaceuticalsalescompanywithlegalqualificationsandagoodreputation.PartyAdesirestoappointPartyBasitsdistributorforthepharmaceuticalslistedin entIheretoandPartyBdesirestoaccepttheaforesaidappointment.為進(jìn)一步明確雙方的權(quán)利和義務(wù)，現(xiàn)根據(jù)《中民合同法》等相關(guān)的規(guī)TofurtherclarifybothParties’rightsandobligations,thefollowingagreementisherebyreachedinaccordancewiththePRCContractlawandotherrelevantlawsandregulations:甲方特此乙方，非獨(dú)家經(jīng)銷商，向本協(xié)議附件一所列城市內(nèi)的醫(yī)院（以下簡(jiǎn)稱“區(qū)域”）銷售附件一中所列明的藥品（以下簡(jiǎn)稱“藥品”）。PartyAherebyauthorizesPartyB,asnon-exclusivedistributorofPartyA,tosellthepharmaceuticalslistedintheAttaentI(hereinafterreferredtoasthe“AuthorizedPharmaceuticals”)totheauthorizedhospitals(hereinafterreferredtoasthe“Territory”)whicharelocatedintheauthorizedcitieslistedintheAttaenthereof.Unlessotherwiseprovidedherein,PartyBshallnotpurchasecommoditieswhicharethesameasorsimilartotheAuthorizedPharmaceuticalsfromanythirdpartyotherthanPartyAorpromotethesamewithintheTerritory.NeithershallPartyB eadistributororanagencyofanythirdpartywhiaycompetewithPartyA.經(jīng)甲方另行同意，乙方可代表甲方參與有關(guān)藥品的投標(biāo)活動(dòng)。乙方明確，即使乙方投標(biāo)失敗，甲方亦無(wú)需就藥品向乙方支付任何補(bǔ)償或承擔(dān)任何責(zé)任，但本協(xié)議另有約定或法SubjecttoawrittenconsentgivenbyPartyAseparay,PartyBmay,onbehalfofPartyA,engageinanybiddingactivityrelatedtotheAuthorizedPharmaceuticals.PartyBconfirmsthat,PartyAhasnoobligationtomakeanycompensationtoorundertakeanyliabilityagainstPartyBwithregardtotheAuthorizedPharmaceuticalsevenifPartyBfailstowinthebidding,unlessotherwiseagreedhereinorforcedbylaws.為提升物流能力，經(jīng)甲方事先同意，乙方可指定有資質(zhì)的、信譽(yù)良好的且經(jīng)甲方認(rèn)可的第配送藥品。乙方明確，該等指定不應(yīng)免除乙方履行本協(xié)議項(xiàng)下的義務(wù)，包括支付本協(xié)議第2.4條所規(guī)定的保證金。Toincreaselogisticscapabilities,uponPartyA’spriorwrittenconsent,PartyBmayappointqualified,reputablethirdpartyacceptedbyPartyAtodelivertheAuthorizedPharmaceuticals.PartyBconfirmsthat,suchappointmentshallnotrelievePartyBfromfulfillingitsobligationshereunder,includingtopaythedepositsetforthinArticle2.4.訂單、價(jià)格和付款方Order,Priceand訂WhenorderingtheAuthorizedPharmaceuticals,PartyBshallsubmitawrittenordertoPartyA,underwhichthefollowinginformationshallbeatleastspecified(hereinafterreferredtoasthe“Order”):訂購(gòu)藥品的藥品通用名、商品名、劑型和規(guī)格thePharmaceuticalsGenericName,CommodityName,DosageFormandSpecificationoftheorderedAuthorizedPharmaceuticals;配送日期，該日期不應(yīng)早于訂單提交日期后的 ]日deliverydate,whichshallnotbeearlierthan[ ]daysafterthesubmissionofanorder;送貨地址及簽收人和deliveryaddressandthenameandcontactsof dIfPartyAfailstoperformthisAgreementorsuffersanylossduetothemistakesinanyorder,PartyBhasnorighttoclaimindemnificationagainstPartyAandifnecessary,PartyAhastherighttodemandanindemnificationfromPartyB.Order乙方除了藥品的第一筆訂單應(yīng)至少提前[]個(gè)月下訂單，其余應(yīng)至少提前[]個(gè)月下訂單（“交貨周期”）。在[]個(gè)工作日內(nèi)，甲方應(yīng)確認(rèn)每一訂單的接收日期，并將其作為交貨周期的開(kāi)始日期（“接受日期”）。藥品應(yīng)在交貨周期內(nèi)發(fā)貨，除非甲方根據(jù)如下條款另行作出確認(rèn)。PartyBshallplaceitsordersatleast[]monthsinadvance(eacha“LeadTime”)exceptforthefirstorderofAuthorizedPharmaceuticalsthatshouldbeorderatleast[]monthsinadvance.Nolaterthan[]workingdays,PartyAshallconfirminwritingdateofreceptionofeachorderwhichshallbeconsideredasthedateofthestartoftheLeadTime(“DateofReceipt”).AuthorizedPharmaceuticalsshallbedeliveredwithintheLeadtimeunlessotherwiseconfirmedinwritingbyPartyApursuanttothetermsbelow.一旦甲方確認(rèn)接受，此訂單將視為一個(gè)實(shí)盤且不可撤銷的、對(duì)雙方產(chǎn)生約束力的訂單。若在接受日期后的[個(gè)月內(nèi)，沒(méi)有接到甲方的任何進(jìn)一步溝通，則應(yīng)視為已接受相關(guān)的訂單且藥品的發(fā)貨日期應(yīng)于上面提及的交貨周期內(nèi)作出。TheordersshallbeconsideredasfirmandirrevocableandshallbindbothPartiesassoonasacceptedinwritingbyPartyA.IntheabsenceofanyfurthercommunicationfromPartyA[]monthaftertheDateofReceipt,therelevantordershallbeconsideredasacceptedanddeliverydateoftheAuthorizedPharmaceuticalsshallbemadewithintheLeadTimesassetforthabove.PurchasePriceand訂購(gòu)藥品的總購(gòu)銷價(jià)格（以下簡(jiǎn)稱“購(gòu)銷價(jià)款”）均應(yīng)以訂單中所載明的數(shù)量及本協(xié)議附件一所列的單價(jià)（以下稱“單價(jià)”）為準(zhǔn)。甲方確認(rèn)接受訂單后的[]天內(nèi)，乙方應(yīng)以銀行轉(zhuǎn)賬的方式向甲方支付購(gòu)銷價(jià)款100%。ThetotalpurchasepriceoftheAuthorizedPharmaceuticals(hereinafterreferredtoasthe“PurchasePrice”)shallbesubjecttothetiesspecifiedinanorderandtheunitpricelistedinAttaentI(hereinafterreferredtoasthe“UnitPrice”).Within[]daysuponPartyAacceptstheorder,PartyBshallpay100%ofthePurchasePricetoPartyAbybanktransfer.WhenPartyAagreesPartyBtoengageinanybiddingactivities,ifthebid-winningpriceoftheAuthorizedPharmaceuticalsislowerthantheUnitPrice,PartyBhasarighttorequestPartyAtoadjusttheUnitPrice,andtheadjustmentrangeshallbenegotiatedbetweentheParties.保證自本協(xié)議簽署之日起[個(gè)工作日內(nèi)且在乙方向甲方遞交本協(xié)議項(xiàng)下第一筆訂單前，乙方應(yīng)當(dāng)向甲方支付[]萬(wàn)元，作為醫(yī)院推廣保證金。前述保證金將于本協(xié)議到期或終止時(shí)或甲方藥品投標(biāo)失敗時(shí)予以返還，但乙方在本協(xié)議期間存在如下任Within[]workingdaysupontheexecutionofthisAgreementandbeforethefirstOrdersubmittedbyPartyBtoPartyA,PartyBshallpayRMB[ ]toPartyAasahospitalpromotiondeposit.SuchdepositwillberefundedwhenthisAgreementexpiresorterminatesorwhenPartyAlosesanybiddingfortheAuthorizedPharmaceuticals,exceptthatPartyBhasanyofthefollowingbehaviorsduringtheTermofthisAgreement:推廣期間擾亂市場(chǎng)（例如亂價(jià)、竄貨disturbthemarketduringthepromotionperiod(e.g.disorderlyprice,sellingtheproductoutoftheTerritory);crosssalesorpliancewithPartyA’ssalesorprice變更藥品的內(nèi)外包裝changeofinsideoroutsidepackagingoftheAuthorized未能遵守本協(xié)議第7.3pliancewiththeundertakingofpurchasesvolumesetforthinArticle7.3herein;甲方認(rèn)為屬于嚴(yán)重本協(xié)議的其他情形othercircumstancesPartyAdeemsasasignificantbreachofthisIncasethecircumstancesetforthinArticle2.4(1)occurs,PartyAhastherighttoforfeitsuchdepositandterminatethisAgreementimmediaywithoutnotice.在如上第(5)種情形中，藥品在區(qū)域內(nèi)一年的采購(gòu)量如低于該年相應(yīng)最低年采購(gòu)量的50%，則甲方?jīng)]收該筆保證金并提前[]個(gè)月通知終止本協(xié)議。InthecircumstancesetforthinArticle2.4(5),ifthevolumesofpurchasesoftheAuthorizedPharmaceuticalsintheTerritoryforonegivenYear,are50%belowtherelevantMinimumAnnualpurchasesinsaidYear,PartyAhastherighttoforfeitsuchdepositandterminatethisAgreementwitha[]monthpriorwrittennotice.發(fā)生如上第(2),(3),(4),(6)種情形的，甲方亦沒(méi)收該筆保證金PartyAhastherighttoforfeitsuchdepositincasethecircumstancesetforthinArticle2.4(2),(3),(4)or(6)occurs.若甲方按照本協(xié)議約定沒(méi)收全部或部分保證金，乙方應(yīng)當(dāng)在30日內(nèi)予以補(bǔ)足。若乙方未補(bǔ)足保證金，甚至在甲方通知后仍不糾正，則甲方立即解除本協(xié)IfPartyAforfeitsallorpartofthedepositunderthisAgreement,PartyBshallmakeupthesumofthedepositwithin30days.IfPartyBfailstomakeupthesumtimely,andevenfailstofulfillitsobligationuponreceiptofthePartyA’notice,PartyAwillbeentitledtoterminatetheAgreementimmediay.配送和驗(yàn)Delivery,Inspectionand配甲方應(yīng)當(dāng)按照訂單要求向乙方配送藥品PartyAshalldelivertheAuthorizedPharmaceuticalstoPartyBinaccordancewiththeorder.Beforedelivery,PartyAshallnotifyPartyBinwritingsothatPartyBmayarrangeforinspectionandacceptance.Whendelivering,PartyAshallcollaterallyprovidethepharmaceuticalsinspectionreportsoftheAuthorizedPharmaceuticalswiththesamebatchnumberandtherelevantentrustagreements(ifapplicable).IfPartyAfailstodelivertheAuthorizedPharmaceuticalsonschedulebecauseofthereasonsunattributabletobothParties,PartyAshalltimelynotifyPartyBofitsdelayofperformanceandthereasonsthereofinwriting.ThePartiesshallinitiateanegotiationtoseekasolutionacceptabletobothParties.驗(yàn)Inspectionand藥品到達(dá)配送地點(diǎn)后，乙方應(yīng)立即組織驗(yàn)收，并當(dāng)場(chǎng)簽署驗(yàn)收單。乙方不得無(wú)故或拖延簽收。自簽署驗(yàn)收單之日起，乙方享有實(shí)際配送的藥品的所并需AftertheAuthorizedPharmaceuticalsarrivedattheplaceofdelivery,PartyBshallimmediayarrangeforinspectionandacceptance,andthereaftersignthedeliveryreceiptonthespot.PartyBshallnotfornoreasonrejectordelaytosignthedeliveryreceipt.Asoftheexecutionofthedeliveryreceipt,theactualdeliveredAuthorizedPharmaceuticalsaretitledtoPartyBandPartyBshallbearalltherisks檢驗(yàn)時(shí)，如發(fā)現(xiàn)實(shí)際配送的藥品與訂單不一致，乙方應(yīng)立即通知甲方予以補(bǔ)充、更換或運(yùn)回。在甲方前往配送地點(diǎn)取回或更換藥品前，乙方應(yīng)自費(fèi)妥善保管Wheninspecting,iftheactualdeliveredAuthorizedPharmaceuticalsarefoundtobeinconsistencewiththeonesundertheOrder,PartyBshallpromptlyinformPartyAtosupplement,replaceorwithdraw.BeforePartyAwithdrawsorreplacestheAuthorizedPharmaceuticalsfromtheplaceofdelivery,PartyBshalldulykeeptheAuthorizedPharmaceuticalsfromfurtherdamagesatitsowncost.因乙方導(dǎo)致甲方未能履行上述義務(wù)的，甲方不承擔(dān)任何責(zé)任PartyAbearsnoliabilitiesforitsfailuretoperformtheaboveobligationsifsuchfailurecanbeattributabletoPartyB.所轉(zhuǎn)Transferof藥品的所自乙方按照本協(xié)議第3.2條的規(guī)定簽署驗(yàn)收單后方才轉(zhuǎn)移至乙方。TheownershipoftheAuthorizedPharmaceuticalsshallbetransferredtoPartyBonlyafterPartyBhassignedthedeliveryreceiptinaccordancewithArticle3.2.質(zhì)量標(biāo)QualityUndertakingsof藥品安全等有關(guān)的規(guī)定。PartyAundertakestoprovidePartyBtheAuthorizedPharmaceuticalsinaccordancewiththeattaentsofthisAgreement,whicharefullycompliancewiththeprovisionsofChinesepharmaceuticalsafetylawsandregulations.質(zhì)量瑕疵或缺FlawsorDefectsin如果乙方發(fā)現(xiàn)藥品因在使用中出現(xiàn)任何瑕疵或缺陷而不符合質(zhì)量標(biāo)準(zhǔn)，乙方應(yīng)在發(fā)現(xiàn)該瑕疵或缺陷后的1個(gè)月內(nèi)向甲方提出通知，并同時(shí)將有關(guān)的樣品寄回給甲方以受其。IftheAuthorizedPharmaceuticalsisfoundbyPartyBnottocomplywiththequalitystandardduetoanyflawordefectappearinginthecourseofuse,PartyBshallnotifyPartyAinwritingwithinonemonthafterthedetectionofsuchflawordefectandshallsimultaneouslysendtoPartyAthesamplesconcernedfor將有瑕疵、缺陷的藥品進(jìn)行，相應(yīng)的費(fèi)用由甲方承擔(dān)。Intheeventthatuponexaminationandinspection,PartyAdemonstratethenoncomplianceoftheAuthorizedPharmaceuticalswiththequalitystandard,PartyAmayrequestPartyBtorecallthedefectiveorflawedAuthorizedPharmaceuticalsatPartyA’scostsinaccordancewiththeapplicablelawsandregulationsinthe無(wú)論何時(shí)，乙方一旦察覺(jué)到藥品出現(xiàn)任何的瑕疵或缺陷，應(yīng)向甲方報(bào)告這些瑕疵動(dòng)，例如，停止經(jīng)銷并通知相關(guān)第）。WheneverPartyBshall eawareofanyflawedordefectiveAuthorizedPharmaceuticals,PartyBshallreportanysuchdefectsorflawstoPartyAandmakeallreasonablecommercialeffortstomitigaterisks,costsandpotentialliabilitiesassociatedtherewith(takingsuchstepsas,forinstance,discontinuingdistributionandnotifyingrelevantthirdparties).質(zhì)量瑕疵或缺陷的ConsequencesofFlawsandDefectsin乙方要求PartyBhastherightto對(duì)有瑕疵或缺陷的藥品進(jìn)行退、換貨，費(fèi)用由甲方承擔(dān)，areplacementoftheflawedordefectiveAuthorizedPharmaceuticalsatPartyA'costs,or在乙方提出要求的30日內(nèi)，對(duì)有瑕疵或缺陷的藥品給與退款。arefundfortheflawedordefectiveAuthorizedPharmaceuticalswithin30daysuponPartyB’writtenrequest.如果雙方在藥品是否符合質(zhì)量標(biāo)準(zhǔn)的認(rèn)定上存在異議，雙方同意將問(wèn)題藥品提交一家由雙方共同選擇的獨(dú)立機(jī)構(gòu)進(jìn)行檢測(cè)。重新檢測(cè)的結(jié)果對(duì)雙方均有約束力，過(guò)錯(cuò)IncaseofdisagreementbetweenthePartiesastothecomplianceoftheAuthorizedPharmaceuticalswiththequalitystandard,thePartiesagreetosubmitthepharmaceuticalsinquestiontoanindependentexpertchosenbythePartiesjointlyfortesting.TheresultsofsuchretestingwillbebindingonthePartiesandthePartyfoundindefaultwillbearthecostsofretesting.PartyBacknowledgesthat,PartyAbearsnoliabilitiesfortheexpiry,ineffectivenessorthequalityreductionoftheAuthorizedPharmaceuticalswhichareattributabletoPartyB(includingimproperuseorkee,包裝標(biāo)Packing方在訂單中特殊包裝要求而產(chǎn)生的附加費(fèi)用，應(yīng)由乙方另行支付。UnlessotherwiserequestedbyPartyBinanorder,PartyAshall,accordingtothebusinesspractices,deliver,storeandpackagetheorderedAuthorizedPharmaceuticals.PartyBshallbeartheadditionalexpensesincurredfromthespecialpackagingrequirementsitproposedinsuchorderseparay.包裝要求變更，一方應(yīng)立即通知另一方，以尋求一個(gè)雙方均可接受的包裝方式。為免疑義，雙方應(yīng)就此另行簽署一份文件。Incaseofchangeofpackagingrequirements,onePartyshallpromptlynotifytheotherPartytoseekforapackingmanneracceptabletobothParties.Toavoiddoubts,thePartiesshallseparayexecuteawritten 推Promotion乙方應(yīng)自負(fù)費(fèi)用在區(qū)域內(nèi)盡力推廣銷售藥品。乙方應(yīng)以合法的方式，按照授銷活動(dòng)。乙方承諾將在每日年初的[]個(gè)月內(nèi)，向甲方遞交在區(qū)域內(nèi)推廣和銷藥品的市場(chǎng)計(jì)劃以及相關(guān)的PartyBshalluseitsdiligenteffortstomarketandselltheAuthorizedPharmaceuticalswithintheTerritoryatitsownexpense.PartyBshallconductitsmarketingactivitiesinalawfulmannerwithappropriateorapplicablestandardsofpharmaceuticalproductpromotionalpractices,fairtrade,faircompetition,andbusinessethics.PartyBundertakestosubmittoPartyAwithin[]monthsfromthebeginningofeachcalendaryear,aproposedmarketingplanwithrelevantbudgettopromoteandmarkettheAuthorizedPharmaceuticalsintheTerritory.推Promotion乙方將使用所有必要及適當(dāng)?shù)囊栽趨^(qū)域內(nèi)成功銷售并推廣該藥品。那些推廣研討會(huì)，在相關(guān)醫(yī)學(xué)雜志上登等。乙方應(yīng)對(duì)其員工進(jìn)行適當(dāng)?shù)呐嘤?xùn)，或可PartyBwilluseallnecessaryandadequatemarketingtoolstosuccessfullypromoteandselltheAuthorizedPharmaceuticalsintheTerritory.Thosemarketingtoolsare,butnotlimitedto:allnecessaryprintmaterial,participationonrelevanttradeshows,conferences,exhibitionsandpromotionalseminars,advertisinginrelevantmedicalmagazinesetc.PartyBshalltrainmembersofitsstaff,asappropriate,orhireandtrainadditionalstaff,soastobeabletocarryoutPartyB'sobligationsunderthis敗Anti-乙方承諾將采取所有合理可行的措施和程序以確保其推廣行為符合全部，特別是有關(guān)敗的規(guī)定。若乙方被發(fā)現(xiàn)在推廣中有任何行為，甲方立即以書PartyBundertakesthatitwilladoptallreasonableandpracticablepoliciesandprocedurestoensureitspromotionscompliancewithalllawsandregulations,particularlytheanti-corruptionrules.IfPartyBisbeofferinganybribesanybribeinpromotions,PartyAisentitledtoterminatethisagreementimmediaywithawrittennoticetoPartyBandrequestPartyBtoundertakeliabilitiesofbreachunderthisAgreement.銷售預(yù)測(cè)與采購(gòu)量保ForecastsandUndertakingofPurchases乙方應(yīng)向甲方提供藥品在區(qū)域內(nèi)銷售的[]個(gè)月滾動(dòng)的銷售預(yù)測(cè)，每一季度更新PartyBshallprovidePartyAwitha[]monthsrollingforecastoftheAuthorizedPharmaceuticalstobesoldontheTerritory,updatedeveryquarter.ThesaidestimatedannualrequirementshallbecommunicatedbyPartyBforinformationpurposesandshallnotconstituteafirmcommitmentbybothParties.超出乙方年度銷售預(yù)測(cè)中相關(guān)部分?jǐn)?shù)量的[]%并且甲方在至少在發(fā)貨日期前的[]個(gè)PartyAshallacceptanddeliveralltheordersplacedbyPartyBinaccordancewiththeestimatedannualrequirementcommunicatedbyPartyBprovidedthatthetiesordereddonotvarybymorethan[]%fromthetiesindicatedintherelevantpartofPartyB’sannualforecastandprovidedthatPartyAreceivestheorderaminimumof[]monthsbeforethedeliverydate.庫(kù)乙方應(yīng)始終保持足夠的藥品庫(kù)存以滿足區(qū)域內(nèi)市場(chǎng)的需求。這些庫(kù)存應(yīng)該足以滿足至少3個(gè)月的預(yù)計(jì)需求。PartyBshallatalltimes,keepadequateinventoriesofAuthorizedPharmaceuticalstomeetthemarketdemandintheTerritory.Theseinventoriesshallbesufficienttocovertheestimatedrequirementforatleast3months.采購(gòu)量保UndertakingofPurchases乙方承諾自本協(xié)議簽署之日起的每一個(gè)年度，在區(qū)域內(nèi)達(dá)到附件二中所述年最低采購(gòu)量（“最低年采購(gòu)量”），該最低年采購(gòu)量應(yīng)由雙方在每個(gè)年度終了前重新審閱并通過(guò)PartyBundertakestoreachintheTerritoryminimumannualsalesrequirementssetforthintheAttaentIIforeachyearperiodfollowingthedateofexecutionoftheAgreement(the“MinimumAnnualPurchases”).SuchminimumannualPurchasesrequirementshallbereviewedandadjustedbybothPartiesbysigningmemorandumbeforeexpirationofeachyearperiod.責(zé)任和義Responsibilitiesand甲方應(yīng)當(dāng)PartyA按照本協(xié)議及其附件的規(guī)定配送藥品delivertheAuthorizedPharmaceuticalsinaccordancewiththisAgreementanditsattaents.件。因甲方未及時(shí)提供投標(biāo)文件而導(dǎo)致投標(biāo)失敗的，乙方可就其所的損IncasePartyAagreesPartyBtoengageinanybiddingactivity,PartyAshallpromptlyprovidecorrespondingbiddingstoPartyB.PartyBhasarighttoclaimanindemnificationagainstPartyAforthelossessufferedfromthefailureofbiddingduetoPartyA’sfailureinprovidingthebiddingstimely.乙方應(yīng)當(dāng)PartyB按照本協(xié)議條款和條件采購(gòu)藥品。除甲方發(fā)生重大違約行為且經(jīng)乙方通知后未能在合理時(shí)間內(nèi)予以糾正外，乙方不得擅自向第采購(gòu)藥品。purchasetheAuthorizedPharmaceuticalsinaccordancewiththetermsandconditionsofthisAgreement.UnlessPartyAmateriallybreachestheAgreementanduponPartyB’snotice,itfailstorectifysuchbreachwithinareasonableperiod,PartyBshallnotarbitrarilypurchasetheAuthorizedPharmaceuticalsfromanythirdparty.在參與藥品的投標(biāo)活動(dòng)過(guò)程中，僅出于投標(biāo)目的合法地使用甲方所提供whenengaginginthebiddingactivitiesrelatedtotheAuthorizedPharmaceuticals,legallyuseanybidding orinformationthatPartyAprovidedforbiddingpurposeonly.reportthebiddingprocessandresultstoPartyAfromtimetotimeandobeytheinstructionandfinaldecisionofPartyA.及時(shí)向甲方通報(bào)區(qū)域內(nèi)藥品的各種不良反應(yīng)和突發(fā)事件，并協(xié)助甲方處informPartyAalltheside-effectsandsuddencasesrelatedtotheAuthorizedPharmaceuticalswithintheTerritoryinatimelymanner,andassistPartyAtodealwithsuchproblems.遵守甲方制定的行為準(zhǔn)則、銷售政策和價(jià)格體系，在甲方事先允許的情況下，不得以低于單價(jià)的價(jià)格銷售藥品，不得以甲方行為準(zhǔn)則或銷售政策的方式銷售、推廣藥品。因乙方原因?qū)е聟^(qū)域內(nèi)市場(chǎng)紊亂的，乙complywithPartyA’scodeofconduct,salespoliciesandpricesystem.WithoutthepriorapprovalofPartyA,PartyBshallnotselltheAuthorizedPharmaceuticalsatthepricelowerthantheUnitPriceandshallnotpromoteorselltheAuthorizedPharmaceuticalsinsuchamannerviolatingPartyA’scodeofconductorsalespolicies.PartyBshallbearallliabilitiesforthemarketdisordersitcausedwithintheTerritory.就甲方為本協(xié)議之目的而向其披露的任何屬于甲方的信息予以keepanyinformationbelongingtoPartyAanddisclosedbyPartyAforthepurposeofthisAgreementin.于每月第5個(gè)工作日前向甲方遞交包含有、開(kāi)票日期、醫(yī)院名稱、submitamonthlysalesreporttoPartyAbeforethefifthworkingdayofeachmonth,whichshallcontain date,hospitalnames,thetitle,dosage,specification,tyoftheAuthorizedPharmaceuticals,etc.于每月第5個(gè)工作日前向甲方遞交包含有批次號(hào)、藥品名稱、劑型、規(guī)submitamonthlyinventoryreporttoPartyAbeforethefifthworkingdayofeaonth,whichcontainsbatchnumber,thetitle,dosage,specification,tyoftheAuthorizedPharmaceuticals,etc.保雙方應(yīng)在本協(xié)議期限內(nèi)自負(fù)費(fèi)用地向信譽(yù)良好的保險(xiǎn)公司投以適當(dāng)?shù)漠a(chǎn)品責(zé)任保險(xiǎn)，保單項(xiàng)下印件及續(xù)費(fèi)收據(jù)的復(fù)印件。EachPartyshallatitsownexpensemaintainwithareputableinsurancecompanyduringtheTermofthisAgreementadequateproductliabilityinsurancepoliciesissuedinsuchcoverageamountsasiscustomaryforsuchParty’sbusinessandconsistentwithindustrystandards.EachPartyshallupontherequestoftheotherPartyproduceacopyofanyrelevantinsurancepolicytogetherwithacopyofthelatestrenewalreceipt.知 lectual甲方保證，其向乙方出售的藥品不任何第的知識(shí)，且乙方對(duì)藥品的銷售亦不會(huì)導(dǎo)致任何第向其提出任何有關(guān)于藥品知識(shí)或其他方面的或主張。PartyAundertakesthat,theAuthorizedPharmaceuticalsitsellstoPartyBdonotinfringeanythirdparty’sinlectualpropertyrights,andPartyB’ssaleoftheAuthorizedPharmaceuticalswillnotentitleanythirdpartytobringanylawsuitormakeanyclaimagainstPartyBfortheinlectualpropertyorotheraspectsoftheAuthorizedPharmaceuticals.乙方保證僅出于本協(xié)議之目的，經(jīng)甲方另行同意后，合法使用藥品的任何知PartyBundertakestolegallyuseanyinlectualpropertyoftheAuthorizedPharmaceuticalsuponaseparaywrittenconsentofPartyAandforthepurposeofthisAgreementonly.乙方確認(rèn)，甲方擁有在區(qū)域內(nèi)、銷售和推廣的藥品的商標(biāo)（以下簡(jiǎn)稱“商標(biāo)”）、材料和規(guī)范性文件之上的任何及所有知識(shí)的完整權(quán)利。乙方應(yīng)僅為甲方的利益而使用該等商標(biāo)、材料和規(guī)范性文件，任何因乙方使用該等授權(quán)商標(biāo)、材料和規(guī)范性文件而累積的商譽(yù)和聲譽(yù)應(yīng)歸于甲方。PartyBacknowledgesthat,PartyAretainsfullownershipofallandanyinlectualpropertyrightsrelatingtothetrademarks(hereinafterreferredtoasthe“AuthorizedTrademark”),marketingmaterialsandregulatorysinrespectofthemarketing,saleandpromotionoftheAuthorizedPharmaceuticalsintheTerritory.PartyBshallusesuchAuthorizedTrademark,marketingmaterialsandregulatorysforthesoleandexclusivebenefitofPartyAandanygoodwillandreputationaccruedinconnectionwithPartyB'suseofsuchAuthorizedTrademark,marketingmaterialsandregulatorysshallaccruetoPartyA.乙方不得且應(yīng)促使其任何關(guān)聯(lián)方不得PartyBshallnot,andshallprocurethatanyofitsaffiliatesdo使用與某一藥品商標(biāo)相同、相或類似的任何其他標(biāo)記或名稱，而該等藥品與藥品存在競(jìng)爭(zhēng)關(guān)系、或與之類似或與藥品具有相同指示；useanyothermarkornamethesameasorconfusinglysimilartothetrademarkinrelationtoapharmaceuticalproductwhichiscompetitivewith,similarto,orindicatedforthesameindicationsastheAuthorized在世界各地與某一藥品商標(biāo)相同或相或類似的任何標(biāo)記或獲取該等標(biāo)記的，而該等藥品與藥品存在競(jìng)爭(zhēng)關(guān)系、或與之類似或與藥register,orprocuretheregistrationof,anymarkthesameasorconfusinglysimilartothetrademarkforapharmaceuticalproductwhichiscompetitivewith,similarto,orindicatedforthesameindicationsastheAuthorizedPharmaceuticalsanywhereintheworld;的外，乙方或其任何關(guān)聯(lián)方或有擁有或使用商標(biāo)。除本協(xié)議有明確外，乙方不得且應(yīng)促使其任何關(guān)聯(lián)方不得就商標(biāo)主張任何權(quán)利或以其他方式給予使用商標(biāo)的；makeanymaterialrepresentationordoanymaterialactwhichmaybetakentoindicatethatithasanyright,titleorinterestinortotheownershiporuseoftheAuthorizedTrademarkotherthanasconferredbythisAgreement.PartyBshallnotandprocurethatanyofitsaffiliatesdonotclaimanyrightintheAuthorizedTrademarkorotherwisegivepermissiontousethesameexceptasexpresslygrantedinthisAgreement;或協(xié)助任何人甲方的知識(shí)challengePartyA’sright,orassistanyoneinachallengetoPartyA’sright,tosuchinlectualpropertyrights;如發(fā)現(xiàn)任何關(guān)于商標(biāo)的、潛在的或行為或任何人提出了授權(quán)商標(biāo)無(wú)效或的任何主張或，乙方或其任何關(guān)聯(lián)方應(yīng)在合理且可行的時(shí)間內(nèi)盡快通知甲方，甲方事先同意，不得就該等事項(xiàng)作出任何informPartyAassoonasreasonablypracticableifPartyBoranyofits esawareofanyinfringement,threatenedinfringementorpassingoff,oranyclaimorallegationbyany ofinvalidityorinfringementinrespectoftheAuthorizedTrademarkandnoneofthemshallmakeanyadmissionorcommentinrelationtosuchmatterswithoutthepriorwrittenconsentofPartyA.期本協(xié)議有效期為[]年，自[年[]月[]日起至[年[]月[]日止。期滿前[]個(gè)月，雙方未就續(xù)約提出異議的，本協(xié)議自動(dòng)續(xù)展1年，除雙方另有約定或中國(guó)另有ThevalidtermofthisAgreementis[]years,commencingfrom[ ]andendedon[ ].IfthePartiesdonotraiseanobjectiontotherenewalofthisAgreementwithin[]monthspriortotheexpiry,thisAgreementshallbeautomaticallyrenewedforoneyear.UnlessotherwiseagreedbetweenthePartiesorprovidedbyChineselawsorregulations,thetermsandconditionsofthisAgreementshallremainunchangedwithintherenewal.違約和終Breachand違Breachof若甲方本協(xié)議第4條之規(guī)定，乙方除要求甲方退、換貨外，還要求甲方賠償。除法律另有規(guī)定外，賠償額度應(yīng)以本協(xié)議第9條下甲IfPartyAbreachesArticle4,excepttorequestforthereplacementorreturnoftheAuthorizedPharmaceuticals,PartyBisalsoentitledtodemandanindemnificationfromPartyA.Unlessotherwiseprovidedbylaws,suchindemnificationshallbelimitedtoPartyA’spolicylimitsassetforthinArticle9.IfsuchpolicylimitsexceedtheamountofthePurchasePrice,suchindemnificationshallbelimitedtothePurchasePrice.乙方若未能按照本協(xié)議之規(guī)定向甲方支付購(gòu)銷價(jià)款，則每遲延一日，乙方應(yīng)按照未付款項(xiàng)的[]%向甲方支付違約金，直至購(gòu)銷價(jià)款得以全部支付為止。IfPartyBfailstopayPartyAthePurchasePriceinaccordancewiththisAgreementanditsattaentshereto,PartyBshallpayPartyAaliquidateddamageof[]%oftheunpaidamountforeachdayitdelays,untilthePurchasePricehasbeenfullypaid.除本協(xié)議另有約定外，任何一方因本協(xié)議項(xiàng)出的、保證及其他Unlessotherwiseagreedherein,anyPartywhoviolatesthedeclarations,undertakingsandotherobligationshereundershallbeartheliabilityforsuchbreachesandifthecounterPartysufferslossestherefrom,suchbreachingPartyshallindemnifythenon-breachingParty.Theindemnificationshallonlyincludealldirectlossesthenon-breachingParty任何一方因本協(xié)議而需支付的任何性質(zhì)的賠償費(fèi)用均應(yīng)以本協(xié)議第2條項(xiàng)下購(gòu)銷價(jià)款為限，但有關(guān)另有規(guī)定的除外。Theindemnification,inwhatevernature,thateitherPartypaysforitsbreachofthisAgreementoritsattaentsshallbelimitedtothePurchasePricedefinedunderArticle2hereof,unlessotherwiseprovidedbylawsorregulations.終發(fā)生如下情形之一的，本協(xié)議終止ThisAgreementshallbeterminateduponanyofthefollowing雙方協(xié)商一致Uponmutual一方因自身原因本協(xié)議且自收到另一方通知后亦未能在合理時(shí)間內(nèi)予以糾正的，守約方通知違約方終止本協(xié)議；IncaseeitherPartybreachesthisAgreementforthereasonsattributabletoitselfanduponthereceiptofthewrittennoticefromtheotherParty,thebreachingPartyfailstorectifysuchbreacheswithinareasonableperiod,thenon-breachingPartyisentitledtonotifythebreachingPartyinwritingtoterminatethisAgreement;一方或進(jìn)入程序時(shí)，另一方通知該方終止本協(xié)議IncaseeitherPartyisbankruptorentersintoliquidationprocedures,theotherPartyisentitledtonotifysuchPartyinwritingtoterminatethis一方按照本協(xié)議第11EitherPartyraisesanobjectiontotherenewalofthisAgreementpursuanttoArticle11hereof;在上一年度終了后雙方未能按照第7.3條確定下一年度年最低采購(gòu)量的；BothPartiesfailtodeterminetheMinimalAnnualPurchasesforthenextyearperiodafterexpirationofthepreviousyearperiod;Othercircumstancessetforthinthis本協(xié)議的終止不應(yīng)影響雙方終止前已產(chǎn)生的債權(quán)關(guān)系TheterminationofthisAgreementshallnotaffectthedebtsorcreditsincurred適用法律和爭(zhēng)議解ApplicableLawandDispute履行而產(chǎn)生或與本合同自身有關(guān)的任何爭(zhēng)議送交有管轄權(quán)的。AllaspectsofthisAgreementshallbeernedbyandinterpretedinaccordancewithPRClaws.ThePartiesshallirrevocablysubmitanydisputearisingfromtheperformanceof,orinconnectiontothisAgreementtoacompetentPeople’sCourt.其他規(guī)完整協(xié)議和附EntiretyandAttaThefollowingattaents,astheinseparablepartofthisAgreement,togetherwiththisAgreementconstituteallunderstandingsandanentireagreementofthepurchaseandsaleoftheAuthorizedPharmaceuticalshereunder.附件一A：藥 entI:AListoftheAuthorized附件一B:省和城 entIBListoftheAuthorizedProvincesand附件二：關(guān)于年最低采購(gòu)量的備忘 entII:MemorandumonMinimumAnnual通本協(xié)議要求或的任何通知或其他信息，均須以形式親手送交、郵寄、傳真，或以雙方同意的其他通訊方式，送至一方指定的如下地址。任何根據(jù)本協(xié)議發(fā)出的通知或其他信息，如果親手送交，則在送交時(shí)被視作已經(jīng)送達(dá)，如果用其他方式發(fā)送，48小時(shí)后被視作已經(jīng)送達(dá)。AnynotificationorinformationasrequiredorpermittedbythisAgreementmustbeinwriting,andmaybedeliveredin ,bypost,fax,orothercommunicationmethodsasmutuallyagreedtothefollowingaddressdesignatedbyeitherParty.IfanynotificationorotherinformationissuedinaccordancewiththisAgreementisdeliveredin ,thenitshallberegardedashavingarrivedwhenitissubmittedtotheotherParty.Ifothermethodsofdeliveryareemployed,thenitshallberegardedashavingarrivedafter48hourscommencingfromthetimeofdeliveryor [市青浦區(qū)318國(guó)道16號(hào)橋南首前云路278號(hào)]PartyA [278QianYunRoad,SouthofBridge16,NationalHighway318,XuJing,QingpuDistrict, PostalCode:傳真 [+8621 [+8621 乙方地址： Party ] PostalCode: 傳真 一方應(yīng)當(dāng)將任何有關(guān)上述情況的變更以形式立即通知另一方EitherPartyshallpromptlynotifyanychangesofaboveinformationtotheotherPartyinwriting.修對(duì)本協(xié)議的任何變更、補(bǔ)充、修改應(yīng)以形式達(dá)成，并經(jīng)雙方簽署后方才生效。Anyalteration,supplementaryoramendmenttothisAgreementshallbeconclud